MULTIPLE SYSTEM ATROPHY MARKET OUTLOOK, 2034 | COMPREHENSIVE INSIGHTS INTO EVOLVING MARKET DYNAMICS, EPIDEMIOLOGY TRENDS, GROWTH OPPORTUNITIES, EMERGING THERAPIES, AND LEADING COMPANIES

The Multiple System Atrophy market is expected to expand in the coming years, driven by the rising prevalence of the disease and the potential introduction of new therapies. Key pharmaceutical and biotech companies, including H Lundbeck A/S, Theravance Biopharma, Brain Neurotherapy Bio, Inc., Ionis Pharmaceuticals, Inc., and Alterity Therapeutics, are actively engaged in the development of therapeutics for Multiple System Atrophy.

DelveInsight's report, "Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast 2034," provides a comprehensive overview of the disease, including historical and projected epidemiology, as well as insights into the Multiple System Atrophy market size, share, trends, and growth opportunities across the seven major markets (7MM) - the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

The report details emerging therapies, current treatment practices, and the market share of individual treatments, along with market size projections from 2020 to 2034. It also assesses current treatment algorithms, identifies key drivers and barriers to market growth, and addresses unmet medical needs to highlight opportunities and evaluate the market's potential.

Download report @ https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple System Atrophy Overview

Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder that affects the autonomic nervous system, which controls involuntary functions such as blood pressure regulation and digestion, as well as movement. Symptoms arise from the gradual degeneration and eventual death of various nerve cells in the brain and spinal cord.

The Multiple System Atrophy Coalition (2021) classifies MSA into two main subtypes based on the predominant symptoms: MSA-predominant Parkinsonism (MSA-P) and MSA-predominant cerebellar ataxia (MSA-C). However, it's important to note that individuals initially diagnosed with MSA-P may later develop symptoms typical of MSA-C, and vice versa, indicating that these classifications can be fluid rather than strictly defined.

Know more about multiple system atrophy market @ https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple System Atrophy Market Key Facts

In 2023, the total diagnosed prevalence of Multiple System Atrophy (MSA) was approximately 51,200 cases across the seven major markets (7MM), and this figure is expected to rise by 2034. DelveInsight estimates that, in Japan, the gender-specific diagnosed prevalence of MSA in 2023 was around 6,600 cases for males and 5,800 cases for females, highlighting a notable gender distribution in diagnosed cases.

DelveInsight's epidemiology model categorizes MSA into two primary subtypes: MSA-predominant Parkinsonism (MSA-P) and MSA-predominant cerebellar ataxia (MSA-C). In 2023, there were approximately 31,100 cases of MSA-P and 20,000 cases of MSA-C in the 7MM, with these numbers expected to grow throughout the forecast period (2024-2034).

The current MSA market primarily consists of off-label therapies that offer only temporary, nonspecific relief, resulting in a market size of nearly USD 171 million in the 7MM in 2023. This market is projected to expand at a compound annual growth rate (CAGR) of 4.9%, driven by the anticipated launch of emerging therapies during the study period (2020-2034).

Market growth is supported by increasing disease prevalence, advancements in diagnostic methods, and greater awareness, which collectively drive demand for new therapies. However, the MSA market also faces significant challenges, including the lack of disease-modifying treatments, high costs, and complex diagnostic processes. Additionally, inconsistent reimbursement policies hinder patient access to available treatments. Addressing these unmet needs through innovative solutions for effective therapies and early diagnosis is essential for enhancing patient care.

In July 2024, Alterity Therapeutics announced promising interim results from the Phase II trial of ATH434 for MSA. The analysis included clinical and biomarker data from seven participants treated for six months, along with neuroimaging data from three participants treated for 12 months. Notably, 43% of participants showed improved scores on the UMSARS Activities of Daily Living Scale after six months, indicating a reduction in disability.

Multiple System Atrophy Market

The market outlook section of the report offers a comprehensive analysis of the historical, current, and projected size of the Multiple System Atrophy market by evaluating the effects of both existing and emerging pipeline therapies. It also includes an in-depth assessment of market drivers and barriers, unmet needs, and emerging technologies that are poised to influence market dynamics.

Additionally, the report provides detailed insights into the trends for each marketed drug and mid- to late-stage pipeline therapies. This evaluation considers factors such as annual therapy costs, mechanisms of action (MoA), routes of administration (RoA), molecule types, competition with other therapies, brand value, and their overall impact on the market.

Know more about how the multiple system atrophy market is growing @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple System Atrophy Epidemiology Assessment

The epidemiology section offers insights into the historical, current, and projected epidemiological trends across the seven major markets (7MM) from 2020 to 2034. It helps identify the factors driving these trends by examining various studies and research. Additionally, this section includes a detailed analysis of the diagnosed and prevalent patient population, future trends, and perspectives from key opinion leaders.

The Report Covers the Multiple System Atrophy Epidemiology, Segmented by -
Total Diagnosed Prevalent Cases of Multiple System Atrophy (MSA)
Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy (MSA)
Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy (MSA)
Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy (MSA)

Multiple System Atrophy Drugs Uptake and Pipeline Development Activities

The drug uptake section examines the adoption rates of recently launched or expected drugs in the Multiple System Atrophy market during the study period. This analysis includes the uptake of various drugs, patient adoption of therapies, and sales performance for each medication. Additionally, the therapeutics assessment highlights which drugs are experiencing the fastest uptake and the factors driving their widespread use, along with a comparison of market shares among the drugs.

The report also details pipeline development activities related to Multiple System Atrophy, providing insights into different therapeutic candidates at various stages of development and the key companies involved in creating targeted treatments. It further analyzes recent developments such as collaborations, acquisitions, mergers, licensing agreements, and other pertinent information regarding emerging therapies.

Learn How the Multiple System Atrophy Market Will Evolve and Grow by 2034 @
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple System Atrophy Therapeutics Analysis

Approximately 20 key companies are actively developing therapies for Multiple System Atrophy. Currently, Biohaven Pharmaceuticals is leading the field, with its drug candidates in the most advanced stage of clinical development among all major players.

The Leading Companies in the Multiple System Atrophy Therapeutics Market Include:
H Lundbeck A/S
Theravance Biopharma
Brain Neurotherapy Bio, Inc
Ionis Pharmaceuticals, Inc.
Alterity Therapeutics
Biohaven Pharmaceuticals
Alterity Therapeutics
Brain Neurotherapy Bio, Inc.
Biogen
Corestem, Inc.
Asklepios BioPharmaceutical
Inhibikase Therapeutics
RETROTOPE
Modag
AC Immune
Vaxxinity
Neuramedy
ProMIS Neurosciences
FAScinate Therapeutics
Wren Therapeutics
Blade Therapeutics
Stealth BioTherapeutics
And Many More

Multiple System Atrophy Drugs Covered in the Report Include:
Ampreloxetine (TD-9855): Theravance Biopharma
Lu AF82422: H Lundbeck A/S
Verdiperstat: Biohaven Pharmaceuticals
ATH434: Alterity Therapeutics
Safinamide: Zambon SpA
And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Key Insights
2. Executive Summary
3. Multiple System Atrophy Competitive Intelligence Analysis
4. Multiple System Atrophy Market Overview at a Glance
5. Multiple System Atrophy Disease Background and Overview
6. Multiple System Atrophy Patient Journey
7. Multiple System Atrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Multiple System Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Multiple System Atrophy Unmet Needs
10. Key Endpoints of Multiple System Atrophy Treatment
11. Multiple System Atrophy Marketed Products
12. Multiple System Atrophy Emerging Drugs and Latest Therapeutic Advances
13. Multiple System Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Multiple System Atrophy Market Outlook (In US, EU5, and Japan)
16. Multiple System Atrophy Access and Reimbursement Overview
17. KOL Views on the Multiple System Atrophy Market
18. Multiple System Atrophy Market Drivers
19. Multiple System Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Contact Us:
Kritika Rehani
krehani@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.